Illumina (NASDAQ:ILMN) Director Daniel Bradbury sold 2,100 shares of the company’s stock in a transaction dated Friday, April 4th. The shares were sold at an average price of $138.44, for a total value of $290,724.00. Following the sale, the director now directly owns 9,924 shares in the company, valued at approximately $1,373,879. The sale was disclosed in a legal filing with the SEC, which is available at this link.Illumina, Inc. (NASDAQ:ILMN) shares after opening at $145.03 moved to $146.56 on last trade day and at the end of the day closed at $135.74. Company price to sales ratio in past twelve months was calculated as 12.25 and price to cash ratio as 14.94. Illumina, Inc. (NASDAQ:ILMN) showed a negative weekly performance of -8.56%.
Incyte (NASDAQ:INCY)‘s stock had its “neutral” rating restated byZacks in a research note issued to investors on Thursday,StockRatingsNetwork.com reports. They currently have a $55.00 price target on the stock. Zacks‘s price target would indicate a potential upside of 5.75% from the company’s current price.Incyte Corporation (NASDAQ:INCY) shares fell -9.38% in last trading session and ended the day on $47.13. INCY return on equity ratio is recorded as 111.10% and its return on assets is -23.90%. Incyte Corporation (NASDAQ:INCY) yearly performance is 109.75%.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced encouraging results from preclinical studies on its antibody drug conjugate, CDX-014. The studies evaluated the anti-tumor activity of CDX-014 against a variety of cell lines.With proof-of-concept preclinical data in its hands, Celldex intends to commence phase I studies on CDX-014 for renal cell carcinoma and other TIM-1 (a molecule highly expressed in renal and ovarian cancers) expressing tumors in 2015. Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares moved down -8.12% in last trading session and was closed at $15.62, while trading in range of $15.51-$17.20. Celldex Therapeutics, Inc. (NASDAQ:CLDX) year to date performance is -35.48%.
Alexion Pharmaceuticals Inc. (Nasdaq:ALXN) announced that the Company will report its financial results for the first quarter ended March 31 2014 on Thursday April 24 2014 before the US financial markets open. Following the release of the financial results Alexion management will conduct a conference call and audio web cast on Thursday April 24 2014 at 10:00 a.m. Eastern Time (ET). Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) weekly performance is -4.80%. On last trading day company shares ended up $144.19. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) distance from 50-day simple moving average is -13.33%. Analysts mean target price for the company is $191.60.
Leave a Reply